The clearance allows human trials for its one-time treatment targeting a genetic eye disease that causes vision loss.
The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.
The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...
GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback